In vitro Ceftaroline Activity against Major Bacterial Pathogens n Russia: Results of Multicenter Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(3):217-226

​ Kozlov R.S., Sukhorukova M.V., Sidorenko S.V., Edelstein M.V., Skleenova E.Yu., Ivanchik N.V., Mikotina A.V., Gostev V.V., Lazareva I.V., Kalinogorskaya O.S., Volkova M.O., Dekhnich A.V.
ceftaroline cephalosporins susceptibility Staphylococcus Streptococcus Enterobacteriaceae
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(3):217-226

Background.

Ceftaroline is a new broad-spectrum cephalosporin with in vitro activity against Gram-positive pathogens, including MRSA, and common Gram-negative pathogens. It is approved for the treatment of acute complicated bacterial skin and skin-structure infections (SSSIs) and community-acquired bacterial pneumonia.

Objective.

To determine in vitro activity of ceftaroline and other clinically available antimicrobials against major bacterial pathogens from different regions of Russian Federation.

Materials and Methods.

A total of 2778 consecutive, non-duplicate isolates were collected during multicentre microbiological in vitro study from 36 geographically distinct cities of Russia during 2008–2012. Only isolates considered to be clinically significant by microbiologist or clinical practice specialist were included in the study. Among tested strains 1000 were Staphylococcus aureus (including 612 MRSA), 954 — Streptococcus pneumoniae, 338 — beta-hemolytic streptococci, 85 — Haemophilus influenzae, 401 — Enterobacteriaceae, mainly ESBL-negative strains of E.coli (n=259) and K. pneumoniae (n=50); the remaining 88 strains were represented by Citrobacter spp., Enterobacter spp., Klebsiella spp., Morganella spp., Proteus spp., Serratia spp. All the isolates were subsequently confirmed using Microflex LT MALDI Biotyper System. The isolates were stored in glycerol-supplemented tryptic soy broth (TSB) at –70 °C until analysis. Minimum inhibitory concentrations (MICs) of antimicrobials were determined by the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method.

Results.

Overall susceptibility rates to ceftaroline were 89,7% for S. aureus (100% for MSSA and 83,2% for MRSA — when using EUCAST or CLSI breakpoints; 0% for MSSA and 0,8% MRSA — when using PK/PD suggested breakpoint of ≤2 mg/l for susceptible strains), 100% for beta-hemolytic streptococci, 99,5% for S. pneumoniae, 75,8% for Enterobacteriaceae (resistant strains were mainly non-E.coli and non-K. pneumoniae AmpC-producing isolates), 98,8% — for H. influenzae.

Conclusions.

The results of the study demonstrate that ceftaroline has high in vitro activity against key bacterial pathogens and could be considered as an option for the therapy of community-acquired bacterial pneumonia and SSSIs in Russia.

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Marina V. Sukhorukova

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Sergey V. Sidorenko

Research Institute of Children’s Infections, Saint-Petersburg, Russia

Mikhail V. Edelstein

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Elena Yu. Skleenova

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Nataly V. Ivanchik

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Anna V. Mikotina

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Gostev V.V.

Research Institute of Children’s Infections, Saint-Petersburg, Russia

Lazareva I.V.

Research Institute of Children’s Infections, Saint-Petersburg, Russia

Kalinogorskaya O.S.

Research Institute of Children’s Infections, Saint-Petersburg, Russia

Volkova M.O.

Research Institute of Children’s Infections, Saint-Petersburg, Russia

Andrey V. Dekhnich

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Козлов Р.С., Голуб А.В. Цефтаролин — sui generis. Клин микробиол антмимикроб химиотер 2013; 15:124- 30.
  • 2. Ishikawa T., Matsunaga N., Tawada H., et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003;11:2427- 37.
  • 3. Iizawa Y., Nagai J., Ishikawa T., et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10:146-56.
  • 4. Sader H.S., Fritsche T.R., Kaniga K., et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49:3501-12.
  • 5. Mushtaq S., Warner M., Ge Y., Kaniga K., LivermoreD.M. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60(2):300- 11.
  • 6. ISO 20776-1:2006 «Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases».
  • 7. Национальный стандарт ГОСТ Р ИСО 20776-1-2010 «Клинические лабораторные исследования и диагностические тест-системы in vitro. Исследование чувствительности инфекционных агентов и оценка функциональных характеристик изделий для исследования чувствительности к антимикробным средствам. Часть 1. Референтный метод лабораторного исследования активности антимикробных агентов против быстрорастущих аэробных бактерий, вызывающих инфекционные болезни».
  • 8. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. CLSI document M100-S24, Wayne, PA: 2014.
  • 9. European Committee on Antimicrobial Susceptibility testing (EUCAST). EUCAST guideline for the detection of resistance mechanisms and specific resistance of clinical and/or epidemiological importance. V 1.02013. Available at URL: http://www.eucast.org/resistance_mechanisms/
  • 10. Эйдельштейн М.В. Выявление бета-лактамаз расширенного спектра у грамотрицательных бактерий с помощью фенотипических методов. Клин микробиол антимикроб химиотер 2001; 3(2):183-9.
  • 11. Sader H.S., Farrell D.J., Mendes R.E., Flamm R.K., Castanheira M., Jones R.N. Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. Diagnostic Microbiology and Infectious Disease 2015; 82:78-84.
  • 12. Flamm R., Sader H., Farrell D., Jones R. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the assessing worldwide antimicrobial resistance evaluation (AWARE) surveillance program. Antimicrob Agent Chemother 2012; 56: 2933-40.
  • 13. Jones R., Mendes R., Sader H. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010; 65(Suppl 4): iv17-31.
  • 14. Li J., Singh R., Ambler J. Probability of target attainment (PTA) and pharmacokinetic/pharmacodynamic (PK/ PD) breakpoint for ceftaroline fosamil 600 mg every 12 h and every 8 h against Staphylococcus aureus. 25th ECCMID, Copenhagen 2015, P1384.
  • 15. Karlowsky J.A., Adam H.J., Baxter M.R., et al. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother 2013; 57:5600-11.
  • 16. Flamm R.K., Sader H.S., Jones R.N. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Diagn Microbiol Infect Dis 2014; 78:437-42.
  • 17. Pfaller M.A., Flamm R.K., Sader H.S., Jones R.N. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis 2014; 78:422-8.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared